Consensus Sabra Health Care REIT, Inc.

Equities

SBRA

US78573L1061

Real-time Estimate Cboe BZX 10:45:20 2024-03-28 am EDT 5-day change 1st Jan Change
14.82 USD +1.68% Intraday chart for Sabra Health Care REIT, Inc. +1.40% +4.17%

Evolution of the average Target Price on Sabra Health Care REIT, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8bd887c93dcdaadd.L32_T77LHDxSijq4aiZ3yawPjqcFE1f_0cSHoqqr96w.XTGOHfa9S0YrxHHyIUAvv81txetPdhKQhqzg0vidmONBEfE4-7FoZWT6UQ~1d279a4d87fff6c796fd4b8b5afff2d0
Deutsche Bank Initiates Coverage on Sabra Health Care REIT With Buy Rating, $21 Price Target MT
Mizuho Adjusts Sabra Health Care REIT's Price Target to $17 From $15, Maintains Buy Rating MT
Stifel Increases Price Target on Sabra Health Care REIT to $16 From $14, Maintains Buy Rating MT
BMO Capital Downgrades Sabra Health Care REIT to Market Perform From Outperform, $16 Price Target MT
Wells Fargo Upgrades Sabra Health Care REIT to Equalweight From Underweight, Raises Price Target to $15 From $11 MT
BofA Securities Upgrades Sabra Health Care REIT to Buy From Neutral MT
Wedbush Starts Sabra Health Care REIT at Outperform With $16 Price Target MT
Jefferies Upgrades Sabra Health Care REIT to Buy From Hold, Adjusts Price Target to $15 From $11 MT
BofA Securities Upgrades Sabra Health Care REIT to Neutral From Underperform, Adjusts Price Target to $14 From $11 MT
Citigroup Adjusts Price Target on Sabra Health Care REIT to $12.50 From $11, Maintains Neutral Rating MT
Barclays Cuts Price Target on Sabra Health Care REIT to $13 From $15, Maintains Equalweight Rating MT
Wells Fargo Starts Sabra Health Care REIT at Underweight With $11 Price Target MT
Truist Securities Adjusts Price Target on Sabra Health Care REIT to $13 From $14, Maintains Buy Rating MT
JMP Securities Downgrades Sabra Health Care REIT to Market Perform From Market Outperform MT
BofA Securities Downgrades Sabra Health Care REIT to Underperform From Neutral, Adjusts Price Target to $13 From $15 MT
Baird Downgrades Sabra Health Care REIT to Neutral From Outperform MT
Berenberg Bank Adjusts Price Target on Sabra Health Care REIT to $17 From $15, Maintains Buy Rating MT
Citigroup Adjusts Price Target for Sabra Health Care REIT to $14.50 From $15, Maintains Neutral Rating MT
Jefferies Downgrades Sabra Health Care REIT to Hold from Buy, Adjusts Price Target to $14 from $15 MT
BMO Capital Trims Sabra Health Care REIT's Price Target to $16.25 From $17, Outperform Rating Maintained MT
Mizuho Securities Upgrades Sabra Health Care REIT to Buy From Neutral, Adjusts Price Target to $15 From $16 MT
Berenberg Bank Adjusts Price Target on Sabra Health Care REIT to $15 From $16, Maintains Buy Rating MT
Fitch Affirms Sabra’s Credit Rating and Outlook BU
Fitch Affirms Sabra Health Care REIT's IDR at 'BBB-'; Outlook Stable AQ
Barclays Downgrades Sabra Health Care REIT to Equalweight From Overweight, Adjusts Price Target to $14 from $16 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
14.58 USD
Average target price
15.91 USD
Spread / Average Target
+9.12%
High Price Target
21 USD
Spread / Highest target
+44.03%
Low Price Target
14 USD
Spread / Lowest Target
-3.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sabra Health Care REIT, Inc.

Deutsche Bank Securities
Mizuho Securities
Stifel Nicolaus
BMO Capital
Wells Fargo Securities
BofA Securities
Wedbush
Jefferies & Co.
Citigroup
Barclays
Truist Securities
JMP Securities
Baird
Berenberg Bank
Credit Suisse
KeyBanc Capital Markets
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings